Tower Research Capital LLC TRC Acquires 4,978 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tower Research Capital LLC TRC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 142.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,472 shares of the biopharmaceutical company's stock after buying an additional 4,978 shares during the quarter. Tower Research Capital LLC TRC's holdings in Regeneron Pharmaceuticals were worth $6,035,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in REGN. Capital International Investors increased its holdings in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the period. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after purchasing an additional 149,124 shares during the period. Finally, Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REGN. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Finally, Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $2.88 during trading hours on Friday, hitting $602.64. 867,564 shares of the company's stock were exchanged, compared to its average volume of 722,806. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The company has a market capitalization of $65.88 billion, a PE ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. The business's 50 day simple moving average is $638.93 and its 200-day simple moving average is $728.60. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the business posted $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.